Therapeutic Candidates for COVID-۱۹: A Comprehensive Review of Antiviral, Immunomodulatory, and Emerging Treatments

Background and Objectives: The coronavirus first appeared in Wuhan, China, in late November ۲۰۱۹, and has since spread to more than one hundred countries. COVID-۱۹ has been declared by the World Health Organization as a Public Health Emergency of International Interest. This has been the result of a virus now having reached pandemic proportions and there not being an effective vaccine or antiviral treatment. In this article, we aim to highlight each current drug being tested for potential effectiveness on this disease.Methodology: The research is a descriptive review conducted by a search in reputable scientific databases, including Scopus, Google Scholar, and PubMed, utilizing the phrases virus, coronavirus, COVID-۱۹, SARS-CoV-۲, and treatment. The latest expertise:given that the development and efficacy of antiviral drugs require substantial time, monotherapy for other diseases may represent the most efficient therapeutic option for a certain condition. Pharmaceuticals with broad-spectrum efficacy, including Bevacizumab, Methylprednisolone, Fingolimod, fluoxetine, Ritonavir, chloroquine Fesnate, remdesivir, and Favipiravir, are currently under investigation as prospective candidates in various clinical trials. Conclusion: To conclude, all these drugs are potentially useful in the prevention and treatment of diseases. But none of these drugs is a cure-all, specific treatment for COVID-۱۹. Therefore, we must continue to search for an effective drug treatment for this disease until we have a proven successful agent available.

کلیدواژه ها:

COVID-۱۹ ، SARS-CoV-۲ ، Antiviral ، Therapeutic Candidates